Additionally, CDDO-Me(bardoxolone methyl) is currently in clinical trials for numerous indications including Pulmonary Arterial Hypertension (PAH) and Chronic Kidney Disease (CKD) but has been demonstrated to hit more molecular targets than NRF2 [19, 20]. The gene discussed is NFE2L2; the disease is pulmonary arterial hypertension.